One CVR will attach to each outstanding share of Atossa common stock as of the close of business on October 19, 2026, and shares and CVRs will transfer together while stapledShares issued after October 19, 2026 will
Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafterCVRs entitle holders to 25% of net proceeds from monetization of Atossa's first
Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafterCVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review
Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathwaysSEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS)
SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclibSEATTLE, July 28, 2026
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndromeSEATTLE, July 21, 2026 /PRNewswire/
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS)
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS)
Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant ConcentrationsTrial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) researchSEATTLE, May 20, 2026 /PRNewswire/
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY TrialsSEATTLE, May 14, 2026 /PRNewswire/ -- Atossa
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approvalSEATTLE, May 4, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.
SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet
